The Company completed the base layout and construction of three scientific research and production branches and subsidiaries in Lhasa, Chengdu and Guanghan as well as the first round construction of major technical transformation projects. The pharmaceutical factories under the direct management of the Company, Chengdu Rhodiola Biopharmaceutical Co., Ltd. and Sichuan Rhodiola Weiguang Pharmaceutical Co., Ltd. passed the national GMP certification at one time respectively.

Established Tibet Rhodiola Pharmaceutical Co., Ltd., with GSP transformation completed and certification passed.

Establish Tibet Rhodiola Tibetan Medicinal Materials Development Co., Ltd.

Won the titles of National High-tech Enterprise and National Leading Enterprise in Agricultural Industrialization.
Had 20 products with independent intellectual property rights, and 4 projects successfully listed in the national special promotion plan.

Annual sales revenue of the Company's own products reached nearly RMB 100 million.

Marked by the successful development of recombinant human brain natriuretic peptide (neoactivin), the Company embarked on a development path with biotechnological drugs and modern Tibetan medicine as its overall structure. At the same time, it was also a victory milestone in the first phase of the overall entrepreneurial stage of Tibet Pharmaceutical.

Awarded special certifications such as National Enterprise Technology Center and National and Local Joint Engineering Research Center for Modernization of Tibetan Medicine.

Awarded the title of National (Second Batch) Innovative Enterprise.

The rhBNP project was included in the national key special support development plan, and a new production line with an annual output of 250,000 vials of lyophilized powder for injection was put into operation. rhBNP was put into large-scale production.

All drug manufacturing units affiliated to the Company carried out a new round of targeted technical transformation according to the cGMP requirements, with an investment of nearly RMB 100 million.

Rhodiola Capsule was included in the 2013 National Essential Drug List.

The Company's annual average sales revenue remained above RMB 1 billion.

The total assets of the Company were about RMB 1.2 billion.

At the end of 2014, Shenzhen Kangzhe Medical joined Tibet Rhodiola Pharmaceutical and formed a strong strategic alliance with Tibet Huaxi Pharmaceutical, the main sponsor of the Company, to complement each other's advantages as two major shareholders. Under this context, Tibet Rhodiola Pharmaceutical set a new goal of becoming bigger and stronger.

The Company made targeted adjustments to the operation mechanism of its own products. It entrusted Shenzhen Kangzhe Medical with the operation of rhBNP and Rhodiola series products, to make full use of its advantages in operation and management, and accelerate the development of two pillar products.

In 2015, the Company's annual profit reached a record high of RMB 80 million.

In 2016, the Company acquired the assets related to IMDUR® product (an international first-line cardiovascular chemical drug) and its brand worldwide (except for the United States). The Company expanded its business layout globally, established and effectively utilized overseas resources to develop the international market for its existing products, which was of great significance for the Company to realize its strategic orientation "from snow-covered plateau to the world".

In 2017, rhBNP was included in Class B of the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance for the first time. Tibet Rhodiola Pharmaceutical won the "Golden Bull Most Valuable Investment Award" for the first time.

In 2019, Tibet Oxygen Big Health Life Sciences Co., Ltd. was established to deeply explore the therapeutical effect and healthcare of Tibetan medicine, and launch big health products that combines traditional Tibetan medicine/TCM-based health maintenance with modern science and technology, to achieve the goal of "Healthy China" with a big health system.

In 2020, Shanghai SynForce Biotechnology Co., Ltd. was established and a vaccine production base located in Lingang New Area, Shanghai Pilot Free Trade Zone was built. Became a shareholder of Beijing Advanced Medical Technologies, Ltd. Inc. to expand its business to medical device sector.

In 2021, the rhBNP production line was expanded. After being continuously included in Class B of the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance in 2017, 2019 and 2021, rhBNP achieved a 10-fold increase in sales volume within 6 years. After the new production line was built, the annual output of rhBNP was expected to reach 15 million vials, which played a positive role in the long-term development of the Company while meeting the market demands.

In 2022, the Company registered and incorporated two wholly-owned subsidiaries in Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, namely Tibet Rhodiola Technology Development Co., Ltd. and Tibet Rhodiola Biopharmaceutical Sales Co., Ltd. to adjust the industrial layout structure, achieve the optimal allocation of elements and accelerate the economic operation of the Company.